Literature DB >> 16533879

Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases.

Dieta Brandsma1, Laurien Ulfman, Jaap C Reijneveld, Madelon Bracke, Martin J B Taphoorn, Jaap Jan Zwaginga, Martijn F B Gebbink, Hetty de Boer, Leo Koenderman, Emile E Voest.   

Abstract

Leptomeningeal metastases are a serious neurological complication in cancer patients and associated with a dismal prognosis. Tumor cells that enter the subarachnoid space adhere to the leptomeninges and form tumor deposits. It is largely unknown which adhesion molecules mediate tumor cell adhesion to leptomeninges. We studied the role of integrin expression and activation in the progression of leptomeningeal metastases. For this study, we used a mouse acute lymphocytic leukemic cell line that was grown in suspension (L1210-S cell line) to develop an adherent L1210 cell line (L1210-A) by selectively culturing the few adherent cells in the cell culture. beta1, beta2, and beta3 integrins were in a constitutively high active state on L1210-A cells and in a low, but inducible, active state on L1210-S cells. Expression levels of these integrins were comparable in the two cell lines. Static adhesion levels of L1210-A cells on a leptomeningeal cell layer were significantly higher than those of L1210-S cells. All mice that were injected intrathecally with L1210-A cells died rapidly of leptomeningeal leukemia. In contrast, 45% long-term survival was seen after intrathecal injection of mice with L1210-S cells. Our data indicate that constitutive integrin activation on leukemic cells promotes progression of leptomeningeal leukemia by increased tumor cell adhesion to the leptomeninges. We argue that an aberrantly regulated inside-out signaling pathway underlies constitutive integrin activation on the adherent leukemic cell population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533879      PMCID: PMC1871936          DOI: 10.1215/15228517-2005-013

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  40 in total

Review 1.  The role of very late antigen-1 in immune-mediated inflammation.

Authors:  Shomron Ben-Horin; Ilan Bank
Journal:  Clin Immunol       Date:  2004-11       Impact factor: 3.969

2.  In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells.

Authors:  B M Chan; N Matsuura; Y Takada; B R Zetter; M E Hemler
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

Review 3.  Integrins: versatility, modulation, and signaling in cell adhesion.

Authors:  R O Hynes
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

Review 4.  Leptomeningeal cancer in leukemia and solid tumors.

Authors:  W A Bleyer; T N Byrne
Journal:  Curr Probl Cancer       Date:  1988 Jul-Aug       Impact factor: 3.187

5.  Novel purification of vitronectin from human plasma by heparin affinity chromatography.

Authors:  T Yatohgo; M Izumi; H Kashiwagi; M Hayashi
Journal:  Cell Struct Funct       Date:  1988-08       Impact factor: 2.212

6.  Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study.

Authors:  M E Olson; N L Chernik; J B Posner
Journal:  Arch Neurol       Date:  1974-02

7.  Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside.

Authors:  J Frick; P S Ritch; R M Hansen; T Anderson
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

8.  Remission induction of meningeal leukemia with high-dose intravenous methotrexate.

Authors:  F M Balis; J L Savitch; W A Bleyer; G H Reaman; D G Poplack
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

Review 9.  Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?

Authors:  C P Kokkoris
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

10.  Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.

Authors:  S T Rosen; J Aisner; R W Makuch; M J Matthews; D C Ihde; M Whitacre; E J Glatstein; P H Wiernik; A S Lichter; P A Bunn
Journal:  Medicine (Baltimore)       Date:  1982-01       Impact factor: 1.889

View more
  7 in total

1.  Retrovirus-transformed erythroleukemia cells induce central nervous system failure in a new syngeneic mouse model of meningeal leukemia.

Authors:  Gordon R Macpherson; Charlotte A Hanson; Delores M Thompson; Christine M Perella; Joan L Cmarik; Sandra K Ruscetti
Journal:  Leuk Res       Date:  2011-09-15       Impact factor: 3.156

2.  AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix.

Authors:  Yuji Piao; Li Lu; John de Groot
Journal:  Neuro Oncol       Date:  2008-10-28       Impact factor: 12.300

3.  Gelsolin expression increases β1 -integrin affinity and L1210 cell adhesion.

Authors:  Jeroen D Langereis; Leo Koenderman; Anna Huttenlocher; Laurien H Ulfman
Journal:  Cytoskeleton (Hoboken)       Date:  2013-05-10

4.  The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.

Authors:  Eric M Thompson; Nathaniel L Whitney; Y Jeffrey Wu; Edward A Neuwelt
Journal:  J Neurosurg Pediatr       Date:  2012-10-19       Impact factor: 2.375

5.  Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report.

Authors:  Ester Simeone; Eleonora De Maio; Fabio Sandomenico; Franco Fulciniti; Secondo Lastoria; Pasquale Aprea; Stefania Staibano; Vincenzo Montesarchio; Giuseppe Palmieri; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Med Case Rep       Date:  2012-05-17

6.  Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Authors:  Sabrina Donnou; Claire Galand; Valérie Touitou; Catherine Sautès-Fridman; Zsuzsanna Fabry; Sylvain Fisson
Journal:  Adv Hematol       Date:  2012-02-12

7.  Constitutive activation of integrin αvβ3 contributes to anoikis resistance of ovarian cancer cells.

Authors:  Romana Dolinschek; Julia Hingerl; Anke Benge; Christian Zafiu; Elisabeth Schüren; Eva-Kathrin Ehmoser; Daniela Lössner; Ute Reuning
Journal:  Mol Oncol       Date:  2020-12-01       Impact factor: 7.449

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.